Allogene Therapeutics provided an interim futility readout from its randomized Phase 2 Alpha3 trial evaluating cema-cel, an off-the-shelf CAR-T, in first-line consolidation large B-cell lymphoma. After day-45 assessment, 58.3% of patients in the cema-cel arm (7 of 12) achieved minimal residual disease negativity compared with 16.7% (2 of 12) in the observation control arm. Allogene said the observed MRD clearance gap exceeds the 25%–30% threshold cited in the literature as potentially linked to meaningful relapse delay. The company continues to enroll 220 participants and expects additional results in 2027 to determine whether the therapy meaningfully improves durable outcomes.